FDA approves H. Lundbeck A/S and Otsuka Pharmaceutical Co Ltd’s anti-psychotic drug Rexulti for the treatment of schizophrenia. The approval follows the results of seven clinical trials, three of which examines its effects on schizophrenia and four of which examines its effects on major depressive disorder (MDD).
Are you a superfan? Join Newslines now and help us create cool news timelines about your favorite people and teams. Register now!
Newslines lets you create cool news timelines about your favorite people and products. Register now!
No network contributions